Get the Stockscreener App
8.73
4.69%
-0.43
After Hours:
8.74
0.010
+0.11%
10 X Genomics Inc stock is traded at $8.73, with a volume of 2.40M.
It is down -4.69% in the last 24 hours and down -18.33% over the past month.
See More
Previous Close:
$9.16
Open:
$8.88
24h Volume:
2.40M
Relative Volume:
0.93
Market Cap:
$1.27B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-4.3218
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
-15.98%
1M Performance:
-18.33%
6M Performance:
-61.34%
1Y Performance:
-76.74%
1-Day Range:
$8.67
$8.99
1-Week Range:
$8.67
$10.49
52-Week Range:
$8.67
$37.86
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
8.73 | 1.27B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
231.63 | 38.81B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
58.03 | 11.36B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
48.24 | 10.16B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
88.37 | 7.67B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.36 | 6.71B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
10X Genomics stock plunges to 52-week low of $9.27 By Investing.com - Investing.com South Africa
10X Genomics stock plunges to 52-week low of $9.27 - Investing.com
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth - Yahoo Finance
10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus.com
10x Genomics: Lower Cost Innovation May Drive A Rebound - Seeking Alpha
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Long Read Sequencing Market Top Companies Study10X Genomics, - openPR
Bruker motion backfires in US patent dispute with 10x Genomics, Harvard - MLex
10x Genomics IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Citigroup Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - Defense World
Strategic Move: Healthcare Giant Zimmer Biomet Taps Communications Veteran from 10x Genomics - Stock Titan
10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN
10x Genomics Dodges Appeal In DNA Analysis Patent Clash - Law 360 UK
10x genomics CEO Serge Saxonov sells $84,393 in stock By Investing.com - Investing.com Australia
Rhumbline Advisers Sells 1,641 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x genomics CEO Serge Saxonov sells $84,393 in stock - Investing.com
Sanctuary Advisors LLC Purchases 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Short Interest in 10x Genomics, Inc. (NASDAQ:TXG) Expands By 34.4% - Defense World
10x Genomics Secures Injunction Against Parse Biosciences' Plann - GuruFocus.com
10x Genomics Secures Injunction Against Parse Biosciences’ Planned ATAC Products - The Malaysian Reserve
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products - Marketscreener.com
10x Genomics secures injunction against Parse Biosciences - Investing.com
10x Genomics gets injunction against Parse Biosciences' ATAC Products (TXG:NASDAQ) - Seeking Alpha
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products – Company Announcement - Financial Times
10 Promising Biotech Stocks to Invest in (March 2025) - Securities.io
ARK Investment Management LLC Purchases 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
SVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Ieq Capital LLC Purchases 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
ING Groep NV Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $56,368.44 in Stock - MarketBeat
Director of 10x Genomics Picks Up 184% More Stock - Simply Wall St
Oxford Nanopore Expands Compatibility With 10x Genomics To Unlock Deeper Insights in Single-Cell Transcriptomics - Technology Networks
Insider Buying: 10x Genomics, Inc. (NASDAQ:TXG) Director Buys 40,000 Shares of Stock - MarketBeat
10x genomics’ president sells $50,602 in stock - Investing.com India
10x genomics CEO Serge Saxonov sells $56,346 in stock - Investing.com India
10x genomics CEO Serge Saxonov sells $56,346 in stock By Investing.com - Investing.com South Africa
10x genomics' president sells $50,602 in stock - Investing.com
10x genomics director Alan Mateo acquires $445,572 in stock - Investing.com
10x Genomics Director Mateo Alan Acquires 40,000 Shares - TradingView
Alberta Investment Management Corp Takes $3.21 Million Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, - GuruFocus.com
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis – Company AnnouncementFT.com - Financial Times
Can 10x Genomics' New 8-Million Cell Platform Transform Genomic Research? - Stock Titan
Harvard, 10x Genomics Settle Patent Dispute With Vizgen - The Harvard Crimson
10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Weiss Ratings Reiterates Sell (E+) Rating for 10x Genomics (NASDAQ:TXG) - Defense World
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference - The Eastern Progress Online
10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Q1 EPS Estimates for 10x Genomics Lowered by Leerink Partnrs - MarketBeat
10x Genomics (NASDAQ:TXG) Lowered to "Hold" Rating by Leerink Partnrs - MarketBeat
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
0.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):